Should I Buy ARGX? ARGX 2026 Analysis

Should You Buy argenx SE (ARGX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

840.500

1 Day change

-0.85%

52 Week Range

934.620

Analysis Updated At

2026/01/28

BUY now for a beginner long-term investor with $50k–$100k. ARGX is in a strong uptrend with accelerating fundamentals (2025/Q3 revenue +96.6% YoY; EPS +272.7% YoY) and broadly bullish Wall Street positioning (multiple target raises and consistent Buy/Overweight ratings). Near-term, the stock looks a bit extended (RSI elevated and price near resistance), but given your impatience and long-term preference, the data supports initiating a position now rather than waiting for a perfect pullback.

Technical Analysis

Trend is bullish. Moving averages are aligned positively (SMA_5 > SMA_20 > SMA_200), indicating sustained upward momentum. MACD histogram is positive and expanding (7.212), confirming bullish acceleration. RSI_6 is high at ~75, suggesting the stock is stretched/overbought short-term even though the broader trend remains up. Key levels: Pivot 827.27 (important near-term support reference), Support S1 788.76 / S2 764.96, Resistance R1 865.78 (near current area) and R2 889.58 (next upside level). Pre-market price ~855.77 (-1.0%) is still near R1, so upside continuation is possible but may be choppier around 865–890. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options positioning leans bullish: open interest put/call at 0.62 and volume put/call at 0.35 imply more calls than puts (risk-on sentiment). Implied volatility is elevated (30D IV ~37.55 vs historical vol ~20.09; IV percentile ~73.6), suggesting the market is pricing meaningful movement and/or demand for optionality. Volume is not unusually heavy vs recent averages (today volume 143 vs 10D avg 225.9), so sentiment is supportive but not showing an extreme ‘crowded’ options chase today.

Technical Summary

Sell

Buy

Positive Catalysts

Continued commercial momentum for Vyvgart (street commentary highlights ongoing launch strength and expanding opportunity in gMG/CIDP).
2026 setup includes multiple potential data catalysts (per analysts) that could broaden the platform value.
Analysts explicitly argue consensus revenue assumptions may be too low, implying room for upward estimate revisions if execution holds.

Neutral/Negative Catalysts

Valuation/expectations risk: at least one notable downgrade (Baird to Neutral) cited the stock as ‘stretched’ and not worth chasing at current levels.
Technical stretch: RSI ~75 and price near resistance increases short-term pullback risk even in an uptrend.
Program-specific risk: prior setback in TED (noted in analyst model changes) shows indication expansion is not guaranteed.
No fresh news catalysts this week, so near-term upside may rely more on technical momentum than event-driven fuel.

Financial Performance

Latest reported quarter: 2025/Q3. Growth is very strong and improving: Revenue $1.127B (+96.60% YoY), Net Income $344.3M (+276.61% YoY), EPS $5.18 (+272.66% YoY). Gross margin is extremely high at ~90.29% (slightly up YoY), supporting a high-quality, scalable earnings profile. Overall, the quarter shows accelerating profitability alongside rapid top-line expansion—consistent with a durable long-term thesis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend is predominantly positive: multiple firms raised price targets in January 2026 (Wells Fargo to $1,317; Morgan Stanley to $1,160; Truist to $1,030; Barclays raised EU target), while Citi slightly trimmed its target to $1,091 but reiterated Buy and called ARGX a top pick. The main counterpoint is Baird’s downgrade to Neutral with an $858 target, arguing expectations are largely priced in. Wall Street ‘pros’ view: best-in-class commercial biotech scaling revenue and margins with additional pipeline/label expansion potential. ‘Cons’ view: strong run leaves less margin for error; valuation and execution risk become more punitive if growth surprises even modestly to the downside. Influential/political trading check: no recent congress trading data available; hedge fund and insider activity described as neutral with no significant recent trend.

19 Analyst Rating

Wall Street analysts forecast ARGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARGX is 1041 USD with a low forecast of 858 USD and a high forecast of 1264 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

3 Hold

0 Sell

Strong Buy

Current: 847.720

Low

858

Averages

1041

High

1264

Current: 847.720

Low

858

Averages

1041

High

1264

Wells Fargo

NULL

Overweight

maintain

AI Analysis

2026-01-20

Reason

Wells Fargo

Price Target

AI Analysis

2026-01-20

maintain

NULL

Overweight

Reason

Wells Fargo raised the firm's price target on Argenx to $1,317 from $1,264 and keeps an Overweight rating on the shares. The firm raises its 2026-2030 Vyvgart estimates by 5%-15%, and highlights FY26 consensus estimate of $5.6B as too low given the growth trajectory. Wells estimates $6.5B assuming single-digit quarter-over-quarter growth in Q1 and low double-digit quarter-over-quarter growth Q2-Q4.

Morgan Stanley

Sean Laaman

Overweight

maintain

2026-01-08

Reason

Morgan Stanley

Sean Laaman

Price Target

2026-01-08

maintain

Overweight

Reason

Morgan Stanley analyst Sean Laaman raised the firm's price target on Argenx to $1,160 from $1,110 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ARGX

Unlock Now

ARGX Should I Buy

ARGX Should I Buy

Should You Buy argenx SE (ARGX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch